In addition to Gvoke, Xeris sales are led by Recorlev, a treatment for endogenous Cushing's syndrome. It has also developed a biopharmaceutical, Keveyis, to treat primary periodic paralysis.

Allison Wey Senior Vice President, Investor Relations and Corporate Communications [email protected] 312-736-1237 ...

First concentrated, ready-to-dilute liquid glucagon available for growing procedural gastroenterology market American Regent to commercialize GVOKE VialDx ™ Availability is expected in the third ...

Patient numbers increased 15% sequentially and 124% year-over-year. Gvoke posted $20.8 million in Q1 revenue, supported by an 8% growth in total prescriptions compared to the prior year period.

The recommended diagnostic dose of Gvoke VialDx for relaxation of the stomach, duodenal bulb, duodenum, and small bowel is 0.2mg to 0.5mg; for the colon, it is 0.5mg to 0.75mg.

By Reuters March 26, 202010:45 PM UTCUpdated ago March 26 (Reuters) - Xeris Pharmaceuticals Inc: * XERIS PHARMACEUTICALS ANNOUNCES $0 COPAY FOR GVOKE™ PFS FOR PEOPLE WITH DIABETES ...